Report Package: “Drug the Undruggable” Technologies

You will also be able to track your order by logging into your account. Dovetailing the two, which make them an increasingly popular method of weight loss https://hotel90.it/79938-naturale-viagra-13501/ over the past decade. Well, in order to make sure you get quality service from the drugstore, there are some tips to consider.

It will not include costs that the clinic may charge you for treatment. Buy doxycycline online from pharmacy.com without having to Ajka visit a pharmacy. To compare clinical signs and bpe lesions between two groups of calves with different age of first exposure to ivermectin treatment.

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Format: PDF
Product Line: Full Report
Product Code: LMFR0032
Release Date: May of 2020
Loading...

Report Package: “Drug the Undruggable” Technologies

This report package includes four full reports for the price of two:

This report provides you with a landscape description and analysis of Targeted Protein Degradation (TPD) technologies and of discovery and development of TPD drug candidates from an industry perspective as of May 2020. This report evaluates the industry landscape of targeted protein degradation with novel PROTAC and molecular glue technologies and compounds. The report is based on the identification and description of 20 major biopharmaceutical and 24 technology-focused companies with targeted protein degradation technologies and research and development activities.

This report provides you with a landscape description and analysis of discovery and development of small molecules against RNA as a drug target from an industry perspective as of September 2019.

This report brings you up-to-date regarding key technologies

  • for identification and validation of intracellular targets,
  • for generation of T-cell receptors (TCR) and TCR fusion proteins,
  • for discovery of TCR-like antibodies, and
  • for construction of cell-penetrating peptides, proteins and antibodies.

This report published in May 2018 brings you up-to-date regarding key TCR-T players, key TCR-T technologies and product candidates, business models, deals and funding opportunities. The report analyzes the TCR-T pipelines and stakeholders in the field, especially focused and diversified TCR-T companies and their relationship with academia and major pharma/biotech. The report highlights the value of TCR-T assets in terms of partnering economic conditions, acquisition prices and financing rounds.

Detailed report descriptions, tables of contents and sample pages from the reports can be found on the respective product page.

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.

Contacts

Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01